Fig 1.
Patient selection flowchart.
Table 1.
Demographics, clinical variables and escalated care of critically ill COVID-19 patients who received prophylactic or therapeutic dose AC.
Fig 2.
Kaplan-Meier survival plots by anticoagulant treatment.
The overall survival functions of critically ill COVID-19 patients who received prophylactic (blue line) or therapeutic (red line) dose anticoagulation are not significantly different from each other (χ2 = 3.13, log rank p = 0.077). However, a clear divergence in survival is noted after 3 weeks ICU admission indicating lower probability of survival among therapeutically anticoagulated patients. Hash marks represent censored data.
Table 2.
Risk of death for ICU patients with COVID-19 by anticoagulant treatment dosage.
Table 3.
Risk of death for COVID-19 patients with 3 or more weeks ICU admission by anticoagulant treatment dosage.
Table 4.
Sample characteristics of survivors and non-survivors with 21 or more days ICU admission who received therapeutic dose anticoagulation.